Evidence map›Paper›PMID 36260222›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2022

Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8

Biaolong Yang, Biaolong Deng, Xiao-Dong Jiao, Bao-Dong Qin, Yi Lu, Weiqi Zhang, Yixian Guo, Shiqi Chen, Dan Li, Bin Li and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Biaolong YangDepartment of Oncology, Changzheng Hospital, Naval Medical University, 200003, Shanghai, China.
Biaolong DengDepartment of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Xiao-Dong JiaoDepartment of Oncology, Changzheng Hospital, Naval Medical University, 200003, Shanghai, China.
Bao-Dong QinDepartment of Oncology, Changzheng Hospital, Naval Medical University, 200003, Shanghai, China.
Yi LuDepartment of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200011, Shanghai, China.
Weiqi ZhangDepartment of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Yixian GuoDepartment of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200127, Shanghai, China.
Shiqi ChenDepartment of Oncology, Changzheng Hospital, Naval Medical University, 200003, Shanghai, China.
Dan LiDepartment of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Bin LiDepartment of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. binli@shsmu.edu.cn.
Yuan-Sheng ZangDepartment of Oncology, Changzheng Hospital, Naval Medical University, 200003, Shanghai, China. doctorzangys@163.com.
Shanghai Changzheng Hospital · CNShanghai Jiao Tong University · CNRenji Hospital · CNShanghai Ninth People's Hospital · CN

Funding

Clinical Trial Funding of Shanghai Changzheng Hospital 2020YLCYJ-Z03, 2020National Natural Science Foundation of China 81702249, 2017National Natural Science Foundation of China 82172710, 2021Science and Technology Commission of Shanghai Municipality 20Y11914400, 2022
6 · The paper itself

Abstract

purposeOur study intended to explore how low-dose anti-angiogenic drugs affected anti-tumor immunity of tumor-infiltrating exhausted CD8

methodsWe tested different doses of anti-VEGFR2 antibody combined with anti-PD1 antibody to treat LUAD in vivo and analyzed tumor-infiltrating CD8

resultsLow-dose anti-VEGFR2 antibody combined with anti-PD1 antibody treatment delayed tumor growth and prolonged the survival time of tumor-bearing mice. The number of tumor-infiltrating CD8

conclusionLow-dose anti-VEGFR2 antibody combined with anti-PD1 antibody therapy promoted anti-tumor immunity and the downregulation of LAYN in tumor-infiltrating CD8

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsCarrier ProteinsCD8-Positive T-LymphocytesImmunotherapyLymphocytes, Tumor-InfiltratingMembrane GlycoproteinsMiceTumor MicroenvironmentCarrier Proteinslayilin protein, mouseMembrane GlycoproteinsAnti-angiogenesis therapyImmunotherapyLAYN (Layilin)Lung adenocarcinoma (LUAD)Tumor-infiltrating exhausted CD8+T

Identifiers

PMID36260222
PMCPMC9747853
OpenAlexW4306776019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.